Insmed Incorporated (NASDAQ:INSM) CFO Sells $1,471,439.82 in Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 18,322 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the transaction, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at $9,545,887.53. The trade was a 13.36 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Tuesday, February 11th, Sara Bonstein sold 13,302 shares of Insmed stock. The stock was sold at an average price of $80.00, for a total value of $1,064,160.00.
• On Thursday, February 6th, Sara Bonstein sold 28,390 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total value of $2,296,751.00.
• On Friday, January 10th, Sara Bonstein sold 1,066 shares of Insmed stock. The stock was sold at an average price of $63.72, for a total value of $67,925.52.
• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The stock was sold at an average price of $65.70, for a total value of $227,979.00.

Insmed Stock Performance

Shares of INSM stock opened at $81.06 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The stock has a 50 day moving average price of $74.29 and a two-hundred day moving average price of $73.59. The company has a market capitalization of $14.50 billion, a P/E ratio of -14.50 and a beta of 1.11.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on INSM shares. Morgan Stanley boosted their price objective on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 target price on shares of Insmed in a research note on Friday. Truist Financial upped their target price on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday. Stifel Nicolaus cut their target price on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday. Finally, Guggenheim upped their target price on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.00.

Institutional Trading of Insmed

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Elequin Capital LP bought a new position in shares of Insmed during the fourth quarter valued at approximately $28,000. Steward Partners Investment Advisory LLC raised its holdings in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares in the last quarter. V Square Quantitative Management LLC raised its holdings in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares in the last quarter. Spire Wealth Management bought a new position in shares of Insmed during the fourth quarter valued at approximately $47,000. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.